Key Morningstar Metrics for Novo Nordisk
- : DKK 311Fair Value Estimate
- : ★★★Morningstar Rating
- : WideMorningstar Economic Moat Rating
- : HighMorningstar Uncertainty Rating
Novo Nordisk NVO received approval from the European Commission on July 15 to market the Wegovy pill as a treatment for obesity and overweight. Shares rose 3%.
Why it matters: With intense competition from Eli Lilly in the injectable GLP-1 category and several disappointing readouts for Novo’s lead pipeline candidate, cagrisema, growth in the Wegovy pill is a bright spot in Novo’s near-term prospects.
- Already launched in the United States in January, in the United Arab Emirates in June, and earlier this month in the United Kingdom, the Wegovy pill is now poised to launch in more European countries in the second half of 2026.
- Most international launches are squarely focused on private sales, building on the cash-pay success in a US market that is more evenly split between insurance and private, cash-pay sales.
The bottom line: While we have increased our global Wegovy pill sales forecast by 2030 to USD 11 billion from USD 9 billion, we’ve factored in higher systematic risk related to its growing cash-pay exposure, and we’re lowering our fair value estimate for Novo Nordisk to DKK 311 per share from DKK 343.
- After reassessing Novo’s risk profile, we’ve raised our WACC estimate to 8.0% from 7.2%. Our beta of 0.7 reflects a combination of biopharma’s generally defensive nature, the cash-pay GLP-1 market’s discretionary nature, and Novo’s own fundamentals and market returns.
- Separately, we’ve lowered our Morningstar Capital Allocation Rating for Novo to Standard from Exemplary, after considering its recent track record for external deals (particularly Catalent) that may not have supported long-term value as much as investment in novel pipeline candidates.
Big picture: While we’re more bullish on Novo’s ability to capitalize on demand for the Wegovy pill, we think shares look overvalued, given a highly competitive market, patent and pipeline uncertainties, and higher sensitivity to the economy than most biopharma peers.
